Immix Biopharma Long Term Debt

The latest long-term debt for IMMX is $890K as of June 2026. That compares with $970K in the prior-year period — down 8.4% year over year. Investors often review this figure alongside Immix Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMMX's long-term debt moved from $970K to $890K — a 8.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Immix Biopharma's operating scale or balance-sheet position.

A long-term debt figure of $890K for IMMX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IMMX's long-term debt ($890K), review year-over-year change from $970K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.